Amendments to the Specification under Revised 37 C.F.R. § 1.121

Please amend the specification to insert the following paragraph at page 1, line 3:

This application is a continuation of U.S. Application No. 09/284,100, filed April 7, 1999; which claims the benefit of priority of International Application No. PCT/US97/18607, filed October 15, 1997, which was published under PCT Article 21(2) in English; which claims the benefit of priority of U.S. Provisional Application Nos. 60/033,046, filed December 10, 1996; 60/032,781, filed December 6, 1996; and 60/028,493, filed October 15, 1996; the disclosure of each of which is explicitly incorporated by reference herein.

Please amend the specification at page 14, line 34 to page 17, line 6 as follows (double-underlining indicating added matter):

A first class of variant(s) is a group of deletion variants of Cys³⁷ to Ser²⁰⁸ of SEQ ID NO:2. These variants include R₁-[Asn⁷¹-Pro²⁰³]-R₂-COOH proteins, and further include an amino acid sequence comprising NH₂-[His⁷²-Ser²⁰⁸]-COOH (also referred to as ΔN35 KGF-2), NH₂-[Leu⁷³-Ser²⁰⁸]-COOH (also referred to as ΔN36 KGF-2), NH₂-[Gln⁷⁴-Ser²⁰⁸]-COOH (also referred to as ΔN37 KGF-2), NH₂-[Gly⁷⁵-Ser²⁰⁸]-COOH (also referred to as ΔN38 KGF-2), NH₂-[Asp⁷⁶-Ser²⁰⁸]-COOH (also referred to as ΔN39 KGF-2), NH₂-[Val⁷⁷-Ser²⁰⁸]-COOH (also referred to as ΔN40 KGF-2) and NH₂-[Arg⁷⁸-Ser²⁰⁸]-COOH (also referred to as ΔN41 KGF-2), in which each may be N-terminally methionylated or non-methionylated, provided however that Cys³⁷ to Ser²⁰⁸ of SEQ ID NO:2 is excluded.

By " R_1 -[Asn⁷¹-Pro²⁰³]- R_2 -COOH" is meant a group of deletion variant(s), wherein [Asn⁷¹-Pro²⁰³] represents residues 71 through 203 of SEQ ID NO:2; wherein R_1 represents a methionylated or nonmethionylated amine group of Asn⁷¹ or of amino-terminus amino acid residue(s) selected from the group:

Tyr

Ser-Tyr

Arg-Ser-Tyr

Val-Arg-Ser-Tyr (SEQ ID NO:9),

His-Val-Arg-Ser-Tyr (SEQ ID NO:10),

Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:11),

Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:12),

Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:13),

Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:14),

Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:15),

Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:16),

Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:17),

Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:18),

Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:19),

Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:20),

Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:21),

Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID

NO:22),

 $Ser-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr \ (SEQ\ ID\ NO:23),$

Ser-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:24),

 $\label{lem:asn-Ser-Ser-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr} Asn-Ser-Ser-Ser-Ser-Ser-Pro-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:25),$

Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:26),

Ala-Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:27),

 $\label{lem:Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr \ (SEQ\ ID\ NO:28),$

Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Ser-Phe-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-

Val-Arg-Ser-Tyr (SEQ ID NO:29),

Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:30),

Val-Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:31),

Met-Val-Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:32),

Asp-Met-Val-Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:33),

Gln-Asp-Met-Val-Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:34),

Gly-Gln-Asp-Met-Val-Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Pre-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:35),

Ala-Leu-Gly-Gln-Asp-Met-Val-Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Pro-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:37),

Gln-Ala-Leu-Gly-Gln-Asp-Met-Val-Ser-Pro-Glu-Ala-Thr-Asn-Ser-Ser-Ser-Ser-Phe-Ser-Ser-Ser-Ser-Ala-Gly-Arg-His-Val-Arg-Ser-Tyr (SEQ ID NO:38), or

and, wherein R₂ represents a carboxy group of Pro²⁰³ or of carboxy-terminal amino acid residues of:

Met

Met-Val

Met-Val-Val

Met-Val-Val-His (SEQ ID NO:40), or

Met-Val-Val-His-Ser (SEQ ID NO:41),

provided however, that R_1 and R_2 are not selected so as to reconstruct Cys³⁷ to Ser²⁰⁸ of SEQ ID NO:2.

Please amend the specification at page 21, line 33 to page 22, line 4 as follows (double-underlining indicating added matter):

Exemplary substitutions of KGF-2 and of variant(s) of KGF-2 (particularly R_1 -[Asn⁷¹-Pro²⁰³]- R_2 -COOH proteins, and more particularly Δ N36 KGF-2, Δ N35 KGF-2, Δ N34 KGF-2, Δ N33 KGF-2, Δ N32 KGF-2, Δ N31 KGF-2, Δ N30 KGF-2, Δ N29 KGF-2, Δ N28 KGF-2, Δ N27 KGF-2 and Δ N26 KGF-2, either methionylated or nonmethionylated) are set forth in the following table: